Direction of Market Influences - Research on Cerus, Arena Pharmaceuticals, Walter Investment Management and AngioDynamics

NEW YORK, NY / ACCESSWIRE / November 3, 2015 / Moments ago, Trader's Choice released new research updates concerning several important developing situations including the following equities: Cerus Corp (NASDAQ: CERS), Arena Pharmaceuticals Inc (NASDAQ: ARNA), Walter Investment Management Corp (NYSE: WAC) and AngioDynamics Inc (NASDAQ: ANGO). Trader's Choice has perfected the profitable art of picking stocks, cutting through the noise to deliver the top trade, every year. The full research reports are being made available to the public on a complimentary basis.

To access our full PDF reports for free, please visit the links below.

============

Full PDF DOWNLOAD Links

(You may have to copy and paste the links into your browser)

CERS Research Report: http://www.traders-choice.com/pdf?s=CERS

ARNA Research Report: http://www.traders-choice.com/pdf?s=ARNA

WAC Research Report: http://www.traders-choice.com/pdf?s=WAC

ANGO Research Report: http://www.traders-choice.com/pdf?s=ANGO

============

Highlights from today's reports include:

On Monday, November 02, 2015, the NASDAQ Composite ended at 5,127.15, up 1.45%, the Dow Jones Industrial Average advanced 0.94%, to finish the day at 17,828.76, and the S&P 500 closed at 2,104.05, up 1.19%.

- The stock of Cerus Corp gained 6.29% to close Monday's session at USD 5.07. The shares of the company moved in the range of USD 5.02 and USD 5.50. A trading volume of 1.39 million shares was recorded, which was greater than its 150-day daily average volume of 0.88 million shares. Over the last five days, Cerus Corp's shares have advanced 9.98% and in the past one month, it has gained a momentum of 11.43%. Additionally, over the past six months, the shares have registered a profit of 8.92%. Moreover, the shares are trading above their 50-day and 200-day moving average of USD 4.89 and USD 4.98, respectively. The stock is at a price to book (PB) ratio of 4.18 as compared to the historical PB ratio of 12.08. Further, the company is trading at a price to sales ratio of 12.66. On Monday, the company announced that Centers for Medicare & Medicaid Services has granted permanent Healthcare Common Procedure Coding System (HCPCS) Level II codes for pathogen-reduced platelet and plasma components.

- Arena Pharmaceuticals Inc's stock increased by 14.29% to close Monday's session at USD 2.16. The company's shares fluctuated in the range of USD 1.85 and USD 2.16. A total of 4.70 million shares exchanged hands, which surpassed its 50-day daily average volume of 3.05 million shares and was also above its 52-week average volume of 4.49 million shares. The 52-week range for the stock is USD 1.60 – USD 6.28. Over the last three days, Arena Pharmaceuticals Inc's shares have advanced 10.20% while in the past one week it has moved down 2.26%. The shares are trading below their 50-day and 200-day moving average of USD 2.29 and USD 3.53, respectively. The stock is at a price to book ratio of 4.26 which is at a discount to its historical PB of 16.15. Additionally, the stock is trading at a price to sales ratio of 11.80. Enterprise value to revenue for the company is 8.01. On November 2, the company and Eisai Inc. announced that six posters regarding lorcaserin HCl data will be presented during ObesityWeek to be hosted by The Obesity Society and the American Society for Metabolic and Bariatric Surgery during November 2-6, 2015.

- Walter Investment Management Corp's stock added 7.61% to close Monday's session at USD 12.87. The company's shares oscillated between USD 11.63 and USD 12.89, marking a new 52-week low during the session. The stock recorded a trading volume of 0.20 million shares, which was above its 50-day daily average volume of 0.16 million shares and below its 52-week average volume of 0.33 million shares. Over the last five days, Walter Investment Management Corp's shares have declined by 9.05% and in the past one month, it has lost 20.16%. The shares are trading below their 50-day and 200-day moving average of USD 15.83 and USD 18.08, respectively. Additionally, the stock is trading at a price to cash flow ratio of 38.93 and price to sales ratio of 29.90. Price to book ratio for the most recent quarter is 0.44. Further, enterprise value to revenue multiple for the company is 14.99.

- AngioDynamics Inc's stock advanced 0.48% to close Monday's session at USD 12.64. The share price vacillated between USD 12.57 and USD 12.81. The stock recorded a trading volume of 0.21 million shares, which was above its 50-day daily average volume of 0.16 million shares as well as higher than its 52-week average volume of 0.17 million shares. Over the last three days, AngioDynamics Inc's shares have advanced 0.56% and in the past one week it has moved up 5.16%. However, in the last six months, the stock has lost 25.03%. The stock is at a price to book ratio of 0.83 vis-a-vis a historical PB ratio of 1.06. Additionally, the stock is trading at a price to cash flow ratio of 13.44 and price to sales ratio ratio of 1.29. The company has an enterprise value to revenue multiple of 1.64 and enterprise value to EBITDA multiple of 11.58. Market capitalization of the company is USD 456.40 million.

--

About Trader's Choice:

Trader's Choice ("TC") produces regular sponsored and non-sponsored reports, articles, stock market blogs, and popular investment newsletters covering equities listed on NYSE and NASDAQ and micro-cap stocks. TC has two distinct and independent departments. One department produces non-sponsored analyst certified content generally in the form of press releases, articles and reports covering equities listed on NYSE and NASDAQ and the other produces sponsored content (in most cases not reviewed by a registered analyst), which typically consists of compensated investment newsletters, articles and reports covering listed stocks and micro-caps. Such sponsored content is outside the scope of procedures detailed below.

TC has not been compensated; directly or indirectly; for producing or publishing this document.

PRESS RELEASE PROCEDURES:

The non-sponsored content contained herein has been prepared by a writer (the "Author") and is fact checked and reviewed by a third party research service company (the "Reviewer"). The Reviewer has reviewed and revised the content, as necessary, based on sound investment judgment and publicly available information which is believed to be reliable. The Reviewer has not performed any independent investigations or forensic audits to validate the information herein. Unless otherwise noted, any content outside of this document has no association with the Author or the Reviewer (collectively referred to as the "Production Team") in any way. The Production Team is compensated on a fixed monthly basis and do not hold any positions of interest in any of the securities mentioned herein. The information in this release has been sourced from a third party data base.

NO WARRANTY

TC, the Author and the Reviewer (collectively referred to as the "Publishers") are not responsible for any error which may be occasioned at the time of printing of this document or any error, mistake or shortcoming. No liability is accepted by the Publishers whatsoever for any direct, indirect or consequential loss arising from the use of this document. The Publishers expressly disclaim any fiduciary responsibility or liability for any consequences, financial or otherwise arising from any reliance placed on the information in this document. Additionally, the Publishers do not (1) guarantee the accuracy, timeliness, completeness or correct sequencing of the information, or (2) warrant any results from use of the information. The included information is subject to change without notice.

NOT AN OFFERING

This document is not intended as an offering, recommendation, or a solicitation of an offer to buy or sell the securities mentioned or discussed, and is to be used for informational purposes only. Please read all associated disclosures and disclaimers in full before investing. Neither TC nor any party affiliated with us is a registered investment adviser or broker-dealer with any agency or in any jurisdiction whatsoever. To download our report(s), read our disclosures, or for more information, visit http://www.traders-choice.com/.

RESTRICTIONS

TC is not available to residents of Belarus, Cuba, Canada, Iran, North Korea, Sudan, Syria or Somalia.

CONTACT

For any questions, inquiries, or comments reach out to us directly at:

E-mail: press (at) traders-choice.com

SOURCE: Trader's Choice


Data & News supplied by www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.